As early as 2013, we have known that a lower baseline prostate-specific antigen (PSA) is associated with a higher overall survival benefit from Provenge (sipuleucel-T)
African American men face many different health disparities with most of the disparities being weighed against them. There is one notable exception, African American (AA) men have a huge, significant overall survival benefit when given Sipuleucel-T (Provenge) equal to 9.5 months over their Caucasian counterparts!
The understanding that the earlier Provenge is used in castrate resistant men with prostate cancer has led many men to ask why not use Provenge even earlier when they are still castrate sensitive? This question is an excellent one which follows the logical next step; however, the answer is surprising!
Recently released and unexpected findings have been announced, contrary to previous understandings, black men who received primary radiation therapy to treat their prostate cancer had lower rates of biochemical cancer recurrence than white men. They also had a lower rate of developing distant metastasis.
Why you should take Provenge (sipuleucel-T) simply using evidence based logic.
Provenge (Sipuleucel-T) is the first FDA approved cancer vaccine and it is still the only immune therapy approved for Prostate Cancer. In a post-hoc analysis it was demonstrated that those men who have lower PSA scores had a superior overall survival. The analysis also showed that men who had Provenge treatment have a lower risk of cardiovascular events.
Getting Provenge is a two step process, understanding what to expect will make your experience easier. You will also need to make some decisions about how you want to get it.
In a prospective, real-world analysis, it was shown that African American men, who have castrate resistant, metastatic prostate cancer, benefited receiving an additional overall survival (OS) benefit when they received Sipuleucel-T (Provenge).